daratumumab,pomalidomide,ciltacabtagene autoleucel,dexamethasone,bortezomib
janssen
['cartitude', 'cartitude-4']
in 15 min dr. hermann einsele will speak about the first phase 3 results from cartitude-4 as part of the plenary abstract session at #eha2023. dr einsele will summarise for mpe the main results of this presentation in an interview. keep an eye out for our social media profiles!
A network of highly efficient, effective and sustainable myeloma and AL amyloidosis patient organisations across Europe